Hologic, Inc.

How big is Hologic, Inc.?

As of Jun 18, Hologic, Inc. has a market capitalization of $17.09 billion, with net sales of $4.03 billion and a net profit of $556.7 million over the latest four quarters.

As of Jun 18, Hologic, Inc. has a market capitalization of 17,093.20 million, classifying it as a Mid Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 4,026.40 million, while the sum of net profit for the same period is 556.70 million.<BR><BR>As of Sep 24, the reporting period shows shareholder's funds of 5,130.00 million and total assets amounting to 9,156.00 million.

What does Hologic, Inc. do?

Hologic, Inc. is a mid-cap company specializing in diagnostics, medical imaging, and surgical products focused on women's health. As of March 2025, it reported net sales of $1,005 million and a net profit of -$17 million, with a market cap of $17.09 billion.

Overview: <BR>Hologic, Inc. is a developer, manufacturer, and supplier of diagnostics products, medical imaging systems, and surgical products with an emphasis on women's health, operating in the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,005 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 17,093.20 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 21.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.19 <BR>Return on Equity: 17.54% <BR>Price to Book: 3.70<BR><BR>Contact Details: <BR>Address: 250 Campus Dr, MARLBOROUGH MA: 01752-3020 <BR>Tel: ['1 508 2632900', '1 858 4108588'] <BR>Fax: 1 302 6555049 <BR>Website: https://www.hologic.com/

Should I buy, sell or hold Hologic, Inc.?

Who are in the management team of Hologic, Inc.?

As of March 2022, Hologic, Inc. is led by Mr. Stephen MacMillan as Chairman, President, and CEO, with Ms. Sally Crawford serving as Lead Independent Director and a diverse board of independent directors.

As of March 2022, the management team of Hologic, Inc. includes Mr. Stephen MacMillan, who serves as the Chairman of the Board, President, and Chief Executive Officer. The board also features Ms. Sally Crawford as the Lead Independent Director, along with several Independent Directors: Mr. Charles Dockendorff, Mr. Scott Garrett, Dr. Ludwig Hantson, and Mr. Namal Nawana. <BR><BR>In summary, as of March 2022, Hologic, Inc.'s management team is led by Mr. Stephen MacMillan, with a diverse board that includes independent directors and a lead independent director.

Is Hologic, Inc. technically bullish or bearish?

As of August 29, 2025, Hologic, Inc. shows a mildly bullish technical trend with mixed signals across time frames, but its underperformance relative to the S&P 500 raises concerns about its long-term outlook.

As of 29 August 2025, the technical trend for Hologic, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD remains bearish, indicating mixed signals across time frames. The weekly RSI shows no signal, but the monthly RSI is bullish, supporting the mildly bullish stance. Daily moving averages are bullish, and the weekly KST is also bullish, further reinforcing the positive outlook. However, the monthly KST and Bollinger Bands are bearish to mildly bearish, suggesting caution. Dow Theory indicates a mildly bullish trend on the monthly scale. <BR><BR>In terms of performance, Hologic has underperformed the S&P 500 year-to-date and over the past year, with returns of -5.30% and -16.46% respectively, compared to the S&P 500's 12.22% and 17.14%. Over three and five years, Hologic's returns are significantly lower than the S&P 500, with 2.17% and 7.39% compared to 70.41% and 96.61%. Overall, the current technical stance is mildly bullish, but the longer-term performance relative to the benchmark raises concerns.

Is Hologic, Inc. overvalued or undervalued?

As of October 17, 2025, Hologic, Inc. is fairly valued with a P/E ratio of 21, despite a recent 3.08% weekly return, but has underperformed over the past year with a -13.20% return compared to the S&P 500's 14.08%.

As of 17 October 2025, the valuation grade for Hologic, Inc. moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 21, an EV to EBITDA of 14.41, and a PEG ratio of 1.65. In comparison, Baxter International, Inc. has a higher P/E of 28.68, indicating a riskier valuation, while Align Technology, Inc. presents a more attractive P/E of 20.46.<BR><BR>Despite Hologic's recent stock performance showing a 3.08% return over the past week compared to the S&P 500's 1.70%, the longer-term outlook reveals a decline with a -13.20% return over the past year versus the S&P 500's 14.08%. This suggests that while Hologic is currently fairly valued, its recent performance may raise concerns for investors.